Capricor Therapeutics Inc Stock
Capricor Therapeutics Inc took a tumble today and lost -€1.500 (-5.290%).
Our community identified positive and negative aspects for Capricor Therapeutics Inc stock for the coming years. 0 users see the criterium "Return on equity" as a plus for the Capricor Therapeutics Inc stock. On the other hand our users think that "Return on equity" could be a problem in the future.
Pros and Cons of Capricor Therapeutics Inc in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Capricor Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Capricor Therapeutics Inc | -5.290% | 10.603% | 40.592% | 121.298% | 3.704% | 532.731% | 515.741% |
| Heron Therapeutics Inc. | -5.000% | -7.083% | -20.452% | -64.977% | -30.521% | -65.330% | -94.528% |
| Evolus Inc | 0.000% | -8.936% | 18.889% | -63.729% | -21.468% | -45.823% | -56.442% |
| Sangamo Therapeutics Inc. | -5.730% | 2.026% | 1.590% | -62.380% | -5.003% | -84.119% | -96.551% |
News
Here's Why This Biotechnology Skyrocketed by 439% in December
Capricor Therapeutics (NASDAQ: CAPR) stock rose an incredible 439.4% in December, according to data provided by S&P Global Market Intelligence. The move followed the company's announcement of
